Conversion of compactin to pravastatin by actinomadura
OwnerArnold L. Demain, Yulin Peng +2inventors
InventorsArnold L. Demain, Yulin Peng, Jacob Yashphe, Joseph Davis
Life of this patent
Estimating the term…
Abstract
A method for converting compactin to pravastatin is described. Compactin is provided and contacted with an agent derived from Actinomadura under conditions in which the agent converts compactin to pravastatin. Also described are an Actinomadura strain, an Actinomadura cell free extract, an Actinomadura hydroxylase, and a method for lowering cholesterol levels in mammals.
Claims36
A method for converting compactin to pravastatin, comprising:
- providing said compactin;
- and
- contacting said compactin with an agent derived from Actinomadura under conditions in which said agent converts compactin to pravastatin.
A cell free extract derived from Actinomadura, comprising an agent that converts compactin to pravastatin.
A hydroxylase from Actinomadura that converts compactin to pravastatin,
- said hydroxylase being a constitutive enzyme;
- the activity of said hydroxylase being stimulated by any of ATP, ascorbic acid and Mg++, but not by Fe++ or Fe+++;
- and
- said hydroxylase being cytochrome P450 system-independent.
Purified Actinomadura 55678, comprising an agent for converting compactin to pravastatin.
A method for treating a mammal to lower the blood cholesterol level of the mammal, comprising:
- providing pravastatin,
- said pravastatin being derived from compactin by contacting said compactin with an agent derived from Actinomadura that converts compactin to pravastatin;
- and
- administering said pravastatin to a mammal in need of such treatment to cause a lower blood cholesterol level in the mammal.
Dependencies are inferred from the claim text.